Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy.

As the first earnings season of 2025 unfolds, investors are likely analyzing financial reports to refine their portfolio strategies.

We recently compiled a list of the 11 Best Stocks To Invest In For Grandchildren. In this article, we are going to take a ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co. (NYSE:LLY), disclosed the sale of shares worth approximately $183.6 million, according to recent filings. The transactions, which ...

The markets have succumbed to the headline pressure around inflation and tariffs, with all three of the major stock market indices trading in the red as of mid-morning. U.S. job growth slowed in ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly ...

BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...